Compare BioNano Genomics Inc (BNGO) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Huntington Bancshares Incorporated — how do they compare? BioNano Genomics Inc trades at $1.24 (market cap $13.66M), while Huntington Bancshares Incorporated trades at $17.77 (market cap $35.93B). The key difference: Huntington Bancshares Incorporated is far larger — about 2630.3× BioNano Genomics Inc's market cap, and Huntington Bancshares Incorporated pays a 3.49% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | HBAN | |
|---|---|---|
Market Cap | $13.66M | $35.93B |
Sector | Health | Financials |
52-Week High | $4.92 | $19.27 |
52-Week Low | $1.06 | $15.02 |
Enterprise Value | $16.26M | — |
Dividend Yield | — | 3.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
HBAN trades at $17.85, up 1.42% today, with a bullish technical signal from moving averages and a consensus price target of $19.78. Recent Q2 2026 earnings matched estimates, with revenue growth and net interest income rising year-over-year. The company targets an 18-19% ROTCE by 2027, supported by efficiency gains and capital returns. However, rising deposit costs and mixed quarterly EPS results present near-term challenges.
The outlook for HBAN is cautiously optimistic, with potential upside from strategic growth initiatives and a reasonable P/E of 13.68. Risks include margin pressure from higher funding costs and volatile earnings performance. Analyst sentiment is balanced, with 44.68% buy ratings, but investors should monitor expense management and loan growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
